A Phase 1b/2a Study of Amilo 5MER for Biomarkers (SAA in Serum) for Inflammatory Bowel Disease (IBD)
Latest Information Update: 13 Aug 2020
At a glance
- Drugs Amilo-5MER (Primary)
- Indications Inflammatory bowel diseases
- Focus Biomarker; Pharmacodynamics
- Sponsors Galmed Pharmaceuticals
- 13 Aug 2020 New trial record
- 06 Aug 2020 According to a Galmed Pharmaceuticals media release, initiation of this phase 1b/2a study for biomarkers (SAA in serum) for IBD is planned in H2 21.